ClinicalTrials.gg
Not yet recruitingNCT07944144Updated Nov 18, 2026

A Phase I/II Study to Learn About the Safety and Effects of a New Medicine Called IPN60350 Alone or in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Solid Tumors

A Phase 1/2 interventional study of IPN60350 in Neoplasms, Neoplasm Metastasis and Neoplastic Processes, sponsored by Ipsen. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionNeoplasm MetastasisRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neoplasm Metastasis
Why
  1. The study's listed conditions name Neoplasm Metastasis, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ipsen · Phase 1/2, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to learn about the safety of a new medicine called IPN60350 and how the body responds to it. Researchers will also look for early signs of antitumor activity in adults with locally advanced or metastatic solid tumors.

All participants in this study will receive IPN60350, either alone or in combination with other anticancer therapies.

The study has two parts.

  • Phase Ia (dose escalation) will test IPN60350 at different dose levels to learn which doses are safe and can be given in future parts of the study.
  • Phase Ib (dose optimization and expansion) will test one or more selected dose levels in a larger number of participants. This will help researchers better understand the safety of IPN60350 and whether it shows early signs of antitumor activity in different tumor types.

Each part will consist of the following periods:

  • A screening period (up to 28 days) to assess whether the participant can take part, requiring at least 1 visit to the study center.
  • A treatment period where IPN60350 is administered in repeating treatment cycles.

The study includes health assessments, blood tests, tissue samples (biopsies), and imaging scans to help researchers better understand the safety of IPN60350 and its potential effects on tumors.

02

Conditions studied

  • Neoplasms
  • Neoplasm Metastasis
  • Neoplastic Processes
  • Pathologic Processes

Browse trials for

03

In context

Neoplasm Metastasis Reclassified

4,051 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.

This study's planned enrollment of 205 is above the median of 50 across 3,275 interventional studies indexed under Neoplasm Metastasis.

Browse Neoplasm Metastasis studies →

Lead sponsor

Ipsen is the lead sponsor of 290 studies on the registry; 18 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.

Compared within Neoplasm Metastasis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥18 years of age, at the time of signing the .
  • or cytologically confirmed locally advanced/ solid tumors.
  • Have at least 1 per version 1.1.
  • Participants with solid tumors who have:

    • disease after receiving at least 1 prior therapy known to provide clinical benefit for their disease based on locally approved standard of care; AND
    • No remaining available approved therapy; or for whom locally approved standard therapies are or not deemed appropriate by the treating investigator.
  • (ECOG) performance status of 0 to 1.
  • use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • (LVEF) >50%.
  • Adequate bone marrow function.
  • Adequate hepatic function and absence of laboratory abnormalities indicating hepatic injury before first dose of study intervention.
  • Adequate renal function before first dose of study intervention.
  • (PT) or international normalized ratio (INR) ≤1.5× (ULN).
  • At the time of screening, a tumor tissue specimen is required for enrollment into phase Ia and phase Ib parts of the study.

Exclusion criteria

Exclusion Criteria:

  • Known second either progressing or requiring active treatment.
  • Has not recovered (i.e., to version 6.0 Grade 1 or to baseline) from previous anticancer therapy-induced AEs. Note: Grade ≤2 AEs with no impact on participant safety are exceptions to this criterion and may qualify for the study, e.g., Grade ≤2 hair loss or stable peripheral neuropathy.
  • Major surgery before receiving the first dose of study treatment. Participants must have adequate wound healing and have recovered from surgery related complications/toxicities prior to first dose.
  • Active or .
  • Significant concurrent, uncontrolled medical condition that would put participants at unacceptable risk from study participation or preclude them from complying with study procedures as per investigator assessment, including, but not limited to renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric disease.
  • History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required , current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging screening.
  • pulmonary disease that may increase the risk of drug-related pneumonitis, including but not limited to pulmonary fibrosis, severe or uncontrolled (COPD), uncontrolled asthma, or ongoing pulmonary infection.
  • Participants with uncontrolled (HIV). HIV-infected participants are eligible if they meet criteria specified in protocol.
  • Known active infection with virus (HBV) OR virus (HCV). Participants are eligible if they meet criteria described in the protocol.
  • History of allogeneic organ transplantation or .
  • Known to study drug, other monoclonal antibodies, or any of the including sensitivity to heparin or heparin-induced thrombocytopenia.
  • Clinically significant cardiovascular or cerebrovascular disease including but not limited to acute myocardial infarction, unstable or severe angina pectoris, endoscopic or open-heart cardiac surgery, stroke, , cerebral hemorrhage, or cerebral infarction, congestive heart failure, arrhythmia, or uncontrolled hypertension.

Note: Additional protocol specified inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
205 participants (estimated)

Study arms

  • Experimental
    Phase Ia: Dose Escalation

    Participants will receive IPN60350, at the assigned dose level.

    Biological: IPN60350

  • Experimental
    Phase Ib: Dose Optimization and Expansion

    At dose optimization, participants will be randomized to receive IPN60350, at one of the two doses of interest.

    Biological: IPN60350

Interventions

  • BiologicalIPN60350

    IPN60350 will be administered at the assigned dose level.

06

What researchers measure

Primary outcomes

  1. Phase Ia: Percentage of Participants With Dose Limiting Toxicities (DLTs)

    Time frame: Up to Day 21 following study drug administration

  2. Phase Ia and Ib: Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is any unfavorable medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A TEAE is defined as an AE with onset from the first dose of study intervention, until the safety follow-up visit, or prior to the start of a new anticancer treatment, whichever is earlier. TEAEs and TESAEs will be graded using National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI CTCAE) version 6.0.

    Time frame: From the first IPN60350 administration until 30 days after last dose (up to approximately 3.5 years)

  3. Phase Ib: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR), as determined by investigator per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

    Time frame: From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)

  4. Phase Ib: Percentage of Participants With Dose Interruptions and Permanent Treatment Discontinuations

    Time frame: From the first IPN60350 administration until 30 days after last dose (up to approximately 3.5 years)

Secondary outcomes

  1. Phase Ia: Time to Maximum Observed Drug Concentration (Tmax) of IPN60350

    Time frame: Within 21 days following drug administration

  2. Phase Ia: Maximum Observed Drug Concentration (Cmax) of IPN60350

    Time frame: Within 21 days following drug administration

  3. Phase Ia: Area Under the Plasma Concentration Time Curve Over a Dosing Interval (AUCtau) of IPN60350

    Time frame: Within 21 days following drug administration

  4. Phase Ia: Tmax of Total Antibody (Tab) of IPN60350

    Time frame: Within 21 days following drug administration

  5. Phase Ia: Cmax of Tab of IPN60350

    Time frame: Within 21 days following drug administration

  6. Phase Ia: AUCtau of Tab of IPN60350

    Time frame: Within 21 days following drug administration

  7. Phase Ia: Tmax of Free Toxin of IPN60350

    Time frame: Within 21 days following drug administration

  8. Phase Ia: Cmax of Free Toxin of IPN60350

    Time frame: Within 21 days following drug administration

  9. Phase Ia: AUCtau of Free Toxin of IPN60350

    Time frame: Within 21 days following drug administration

  10. Phase Ia and Ib: Percentage of Participants With Treatment-Emergent Anti-drug Antibodies (ADA), Including Binding and Neutralizing Antibodies.

    Time frame: From pre-dose on Day 1 up to end of study (up to approximately 3.5 years)

  11. Phase Ia: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with BOR of CR or PR, as determined by investigator per RECIST version 1.1.

    Time frame: From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)

  12. Phase Ib: Duration of Response (DoR)

    DoR is defined as the time from the first documented evidence of CR or PR until progressive disease, as determined by investigator per RECIST version 1.1, or death from any cause, whichever occurs first.

    Time frame: From first confirmed documented response (CR or PR) to the earliest date of documented disease progression, new anticancer therapy or death due to any cause (up to approximately 3.5 years)

  13. Phase Ib: Progression-free Survival (PFS)

    PFS is defined as the time from the date of first IPN60350 administration to the date of the first documented disease progression, as determined by investigator per RECIST version 1.1, or death due to any cause, whichever occurs first.

    Time frame: From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)

  14. Phase Ib: Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with BOR of CR, PR or stable disease (SD), as determined by investigator per RECIST version 1.1

    Time frame: From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2030, 42 months later.

Of 129 industry-sponsored phase 1/2 interventional studies under Neoplasm Metastasis, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 89. This study's planned 42 months is below that.

Counting every sponsor, half of 215 studies reached it within 62 months; a quarter within 41 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 18, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jun 28, 2030
CompletionEst.
Sep 30, 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944144
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jun 28, 2030 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Ipsen Clinical Study Enquiries
Contact
clinical.trials@ipsen.com
See email

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion